Sponsor Overview
Explore verified public information about Kazia Therapeutics Limited's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“In rare circumstances, after careful discussion with the treating clinician, Kazia is sometimes able to provide its drug candidates for compassionate use on an individual named patient basis.”
“Kazia will consider providing a requesting physician with preapproval access to a specific Kazia investigational drug, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.”
Reagan-Udall Foundation Insights
Available Therapies via Single-Patient EA Paxalisib (formerly known as GDC-0084) Disease/Category-Specific EA Policies/Criteria https://www.kaziatherapeutics.com/researchpipeline/paxalisib
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.